Abiopharma

Gold Reserve Announces Intention to Make Further CVR/Bonus Settlement Offers, to Make Offers to Optionholders, and to Amend Equity Incentive Plan

DeFi Technologies Inc. Announces Second Quarter 2026 Financial Results with Revenue of $7.8 Million, Operating Loss of $2.3 Million, and Maintained Strong Balance Sheet

UTHR: Notification

Bristol Myers Squibb - U.S. FDA Grants Accelerated Approval to Bristol Myers Squibbs First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibbs First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

AS Watson Expands Partnership With NCR Voyix Through Global Voyix Commerce Platform Agreement

Mativ Announces Participation in Upcoming Investor Conferences

Harmonic to Participate in Upcoming Investor Conferences

IM Cannabis Corp. Announces Second Quarter and First Half 2026 Financial Results